Nektar Therapeutics
NasdaqCM:NKTR Stock Report
Nektar Therapeutics Future Growth
Future criteria checks 1/6 Nektar Therapeutics's earnings are forecast to decline at 6.7% per annum while its annual revenue is expected to grow at 12.8% per year. EPS is expected to grow by 6.2% per annum. Return on equity is forecast to be -224.5% in 3 years.
Key information
-6.7%
Earnings growth rate
Pharmaceuticals earnings growth 23.8% Revenue growth rate 12.8% Future return on equity -224.5% Analyst coverage Good
Last updated 08 Nov 2024
Recent future growth updates
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Consensus EPS estimates fall by 12% Mar 11
Price target decreased by 83% to US$0.50 Feb 11
Price target increased by 21% to US$2.88 Sep 21
Price target increased by 14% to US$2.70 Aug 14
Price target decreased by 7.3% to US$2.35 Aug 01
Show all updates
Nektar Therapeutics Provides Earnings Guidance for the Full Year of 2024 Nov 09
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 08
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 08 Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 06
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics (NasdaqCM:NKTR) for $90 million. Nov 05
New major risk - Revenue and earnings growth Nov 04
Nektar Therapeutics to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Nektar Therapeutics Announces Publication in Nature Communications of Results from Phase 1B Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases Oct 29
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking Oct 18
Nektar Therapeutics Announces Publication in Blood of Phase 1 Data for Novel II-15 Agonist NKTR-255 in Combination with Autologous CD19-22 Car-T Cell Therapy in Patients with B-Cell Acute Lymphoblastic Leukemia Oct 17
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Nektar Therapeutics to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding Jun 19
First quarter 2024 earnings: EPS and revenues exceed analyst expectations May 12
Nektar Therapeutics to Report Q1, 2024 Results on May 09, 2024 May 03
Nektar Therapeutics, Annual General Meeting, Jun 05, 2024 Apr 28
New major risk - Share price stability Apr 19 Nektar Therapeutics announced that it has received $30 million in funding from TCG Crossover Management, LLC Mar 20
Consensus EPS estimates fall by 12% Mar 11
Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat Mar 06
Nektar Therapeutics Announces Initiation of Phase 2B Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata Mar 05 Nektar Therapeutics announced that it expects to receive $30 million in funding from TCG Crossover Management, LLC Mar 04
Nektar Therapeutics to Report Q4, 2023 Results on Mar 04, 2024 Feb 27
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise Feb 15
Price target decreased by 83% to US$0.50 Feb 11
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry Dec 31
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 29
Nasdaq States Nektar Therapeutics Eligible for an Additional 180 Calendar Day Period, or Until May 20, 2024, to Regain Compliance with the Minimum Bid Price Requirement Nov 28
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth? Nov 06
Nektar Therapeutics to Report Q3, 2023 Results on Nov 07, 2023 Nov 01
Nektar Therapeutics Presents New Responder Data for Rezpegaldesleukin, A First-In-Class Selective Regulatory T-Cell Therapy Oct 14
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate Nktr-255 in Combination with C-Til051 in Advanced Non-Small Cell Lung Cancer Sep 28
Price target increased by 21% to US$2.88 Sep 21
Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-To-Severe Atopic Dermatitis Sep 14
Price target increased by 14% to US$2.70 Aug 14
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 09
New major risk - Share price stability Aug 08
Nektar Therapeutics Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company Aug 08
Nektar Therapeutics to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Price target decreased by 7.3% to US$2.35 Aug 01
New minor risk - Market cap size Jul 25
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 2000 Index Jun 25
New minor risk - Market cap size Jun 22
Nektar Therapeutics Receives Notice from The Nasdaq Global Select Market Due to Non-Compliance with the Minimum Bid Price Rule Jun 03
Price target increased by 18% to US$3.00 May 16
Consensus EPS estimates fall by 63%, revenue upgraded May 16
Price target decreased by 7.8% to US$2.70 May 11
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 11
Nektar Therapeutics Reports Impairment of Goodwill for the First Quarter Ended March 31, 2023 May 10
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth? Apr 24
Full year 2022 earnings: EPS exceeds analyst expectations Mar 01
Price target decreased by 21% to US$3.60 Feb 24
CEO, President & Director recently sold US$59k worth of stock Feb 23
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely Jan 24
Insufficient new directors Jan 01
CEO, President & Director recently sold US$136k worth of stock Nov 21
Insider recently sold US$48k worth of stock Nov 19
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, A Novel Polymer-Conjugated Human IL-15, Improves Efficacy of CD19-Targeted CAR-T Cell Immunotherapy Nov 10
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 05
Nektar Therapeutics to Report Q3, 2022 Results on Nov 03, 2022 Oct 26
Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC). Oct 08
Independent Director notifies of intention to sell stock Sep 17
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (Eadv) Congress Sep 07
Insider notifies of intention to sell stock Aug 22
CEO, President & Director recently sold US$65k worth of stock Aug 20
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans? Aug 19
Nektar Therapeutics Announces Preclinical Publication of Data for NKTR-255 and Its Observed Improvement of NK Cell Function in Multiple Myeloma Aug 17
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 05
Nektar Therapeutics Provides Earnings Guidance for the Year 2022 Aug 05
Nektar Therapeutics to Report Q2, 2022 Results on Aug 04, 2022 Jul 28
Nektar: Time To Abandon Ship Jul 17 Nektar Promotes Jillian B. Thomsen to Senior Vice President
Nektar promotes internal executive to CFO role Jul 01
Nektar Therapeutics(NasdaqGS:NKTR) dropped from Russell 1000 Dynamic Index Jun 26
Price target decreased to US$4.83 May 31
Nektar Therapeutics Reviews Interim Efficacy and Safety Data from the Ongoing Phase 2 Double Blinded, Placebo-Controlled Study May 24
CEO, President & Director recently sold US$144k worth of stock May 20
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully May 11
First quarter 2022 earnings: EPS exceeds analyst expectations May 06
Price target decreased to US$5.96 May 02
Nektar Therapeutics, Annual General Meeting, Jun 08, 2022 May 02
Consensus forecasts updated Apr 27
John Northcott Step Down as Senior Vice President and Chief Commercial Officer of Nektar Therapeutics Apr 26
Nektar Therapeutics and Bristol-Myers Squibb Company Announce Update on Clinical Development Program for Bempegaldesleukin (Bempeg) in Combination with Opdivo (Nivolumab) Apr 16
After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline Apr 04
Consensus forecasts updated Mar 15
Earnings and Revenue Growth Forecasts NasdaqCM:NKTR - Analysts future estimates and past financials data (USD Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 81 -195 -198 -153 7 12/31/2025 80 -178 -170 -147 7 12/31/2024 91 -154 -111 -148 6 9/30/2024 93 -168 -178 -177 N/A 6/30/2024 93 -177 -175 -175 N/A 3/31/2024 90 -176 -189 -189 N/A 12/31/2023 90 -276 -193 -193 N/A 9/30/2023 88 -294 -204 -203 N/A 6/30/2023 88 -307 -245 -244 N/A 3/31/2023 89 -415 -269 -267 N/A 12/31/2022 92 -368 -310 -304 N/A 9/30/2022 95 -454 -409 -398 N/A 6/30/2022 96 -525 -430 -416 N/A 3/31/2022 103 -491 -440 -424 N/A 12/31/2021 102 -524 -428 -413 N/A 9/30/2021 100 -495 -371 -360 N/A 6/30/2021 105 -474 -321 -311 N/A 3/31/2021 126 -429 -322 -312 N/A 12/31/2020 153 -444 -321 -313 N/A 9/30/2020 163 -439 -349 -340 N/A 6/30/2020 163 -429 -368 -356 N/A 3/31/2020 137 -460 -347 -326 N/A 12/31/2019 115 -441 -355 -329 N/A 9/30/2019 121 -427 -352 -321 N/A 6/30/2019 119 -424 -352 -324 N/A 3/31/2019 1,184 657 671 690 N/A 12/31/2018 1,193 681 704 718 N/A 9/30/2018 1,249 746 747 755 N/A 6/30/2018 1,374 903 N/A 920 N/A 3/31/2018 321 -129 N/A -98 N/A 12/31/2017 308 -97 N/A -80 N/A 9/30/2017 250 -105 N/A -52 N/A 6/30/2017 133 -209 N/A -173 N/A 3/31/2017 131 -198 N/A -128 N/A 12/31/2016 165 -154 N/A -117 N/A 9/30/2016 167 -165 N/A -140 N/A 6/30/2016 191 -130 N/A -126 N/A 3/31/2016 181 -134 N/A -160 N/A 12/31/2015 231 -81 N/A -73 N/A 9/30/2015 211 -73 N/A -23 N/A 6/30/2015 284 6 N/A -55 N/A 3/31/2015 290 26 N/A -16 N/A 12/31/2014 201 -54 N/A -142 N/A 9/30/2014 212 -56 N/A -64 N/A 6/30/2014 140 -143 N/A -37 N/A 3/31/2014 146 -153 N/A -63 N/A 12/31/2013 149 -162 N/A -39 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NKTR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NKTR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NKTR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NKTR's revenue (12.8% per year) is forecast to grow faster than the US market (8.9% per year).
High Growth Revenue: NKTR's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NKTR is forecast to be unprofitable in 3 years.
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
